Respiratory Syncytial Virus Mother and Infant Protection Program (RSV-MIPP) data

NCIRS is monitoring the rollout of the RSV-MIPP by assessing the uptake of Abrysvo in women of child-bearing age and of nirsevimab in children aged under two years.

Immunisation coverage data and reports

The RSV-MIPP has two components – an RSV vaccine provided under the National Immunisation Program (NIP) and a monoclonal antibody provided through state and territory programs.

The vaccine component of the program commenced on 3 February 2025 and provides Medicare-registered pregnant women across Australia with free access to the RSV vaccine Abrysvo under the NIP.

A single dose of the vaccine is recommended for pregnant women from 28 weeks gestation and provides protection for their infant against severe RSV disease. Administration prior to 36 weeks gestation is encouraged because, if the infant is born within two weeks of the mother receiving the vaccine, there is insufficient time for the immune response to develop.

In addition to the vaccination program for pregnant women, the long-acting RSV monoclonal antibody nirsevimab is available for free to eligible infants under varying state/territory funded infant programs. It is recommended for infants:

whose mothers did not receive a dose of Abrysvo during pregnancy
who were born within two weeks of the mother receiving Abrysvo
who are at increased risk of severe RSV disease, regardless of maternal vaccination status.

Nirsevimab is also recommended for children up to 24 months of age entering their second RSV season who are at risk of severe RSV disease.

Click on the tiles below to explore the data.

Data will be updated monthly and currently focus on uptake of the NIP maternal Abrysvo program only.

The infant program has commenced across all states and territories. As rollout dates varied across jurisdictions, nirsevimab uptake data will be included in future updates.